Stoke Therapeutics, Inc. Profile Avatar - Palmy Investing

Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Aug…

Biotechnology
US, Bedford [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of STOK's Analysis
CIK: 1623526 CUSIP: 86150R107 ISIN: US86150R1077 LEI: - UEI: -
Secondary Listings
STOK has no secondary listings inside our databases.